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Abstract
Background: It is known that mitochondria play an important role in certain cancers (prostate, renal, breast, or colorectal)
and coronary disease. These organelles play an essential role in apoptosis and the production of reactive oxygen species; in
addition, mtDNA also reveals the history of populations and ancient human migration. All these events and variations in the
mitochondrial genome are thought to cause some cancers, including prostate cancer, and also help us to group individuals
into common origin groups. The aim of the present study is to analyze the different haplogroups and variations in the
sequence in the mitochondrial genome of a southern European population consisting of subjects affected (n = 239) and
non-affected (n = 150) by sporadic prostate cancer.
Methodology and Principal Findings: Using primer extension analysis and DNA sequencing, we identified the nine major
European haplogroups and CR polymorphisms. The frequencies of the haplogroups did not differ between patients and
control cohorts, whereas the CR polymorphism T16356C was significantly higher in patients with PC compared to the
controls (p = 0.029). PSA, staging, and Gleason score were associated with none of the nine major European haplogroups.
The CR polymorphisms G16129A (p = 0.007) and T16224C (p = 0.022) were significantly associated with Gleason score,
whereas T16311C (p = 0.046) was linked with T-stage.
Conclusions and Significance: Our results do not suggest that mtDNA haplogroups could be involved in sporadic prostate
cancer etiology and pathogenesis as previous studies performed in middle Europe population. Although some significant
associations have been obtained in studying CR polymorphisms, further studies should be performed to validate these
results.
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Introduction
Prostate cancer is one of the most prevalent cancers diagnosed
in men. Prostate cancer incidence is characterised by a large
geographic variability, ranging from few cases (approximately 4–7
per 100,000) in Asian countries to 70–100 cases per 100,000 in
Nordic European countries and North America. In Italy and
Spain, the rates are rather low in comparison with those observed
in other Western countries and are the lowest among the
European Union (EU) countries [1,2]. However, few conclusive
studies have been performed with regard to the genetics of this
cancer. Some linkage studies [3] ascribe an important role to genes
such as ELAC2 (elaC homolog 2 (E. coli)) at 17q, RNASEL at
1q24–25 (Hereditary Prostate Cancer gene 1 (HPC1)) [4], and
MSR1 (macrophage scavenger receptor 1) at 8p22, which contain
inactivating mutations in affected members in at least one prostate
cancer family. Nevertheless, other studies have not confirmed the
associations seen with some of these genes. This is the case with the
lack of association between prostate cancer and the RNASEL (29,
59-Oligoadenylate-dependent RNase L) gene in a Swedish
population [5]. The situation is even more complicated in
sporadic prostate cancer where, because of its genetic heteroge-
neity, it has been suggested that many gene loci, rather than a
single specific gene, are involved in the predisposition to this
cancer [6]. Two different types of mutations can be found in
cancer. Somatic mutations occur in a single cell in developing
somatic tissue. The generation of reactive oxygen species (ROS)
causes mutations in mitochondrial of somatic cells. In contrast,
germinal mutations occur in the germ line and can be passed on to
the next generation, as in this study [7]. Mutations in mtDNA
(mitochondrial DNA) have been shown to fulfil all of the criteria
required for pathogenic mutations causing prostate cancer [8].
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Some of the mutations are in the COI (cytochrome c oxidase) [8]
or COX7A2 (cytochrome c oxidase subunit VIIa polypeptide 2)
[9] gene, and some mutations are directly related to known
haplogroups involved in the association between mtDNA variants
and complex diseases such as renal and prostate cancer [10]. It has
been suggested that mtDNA mutations can be separated into two
types: adaptative and tumorigenic (non-adaptative). Adaptative
mtDNA mutations are milder mutations observed in different
populations [11]. Tumorigenic mutants include mutations such as
heteroplasmic insertions and deletions [11]. Mutations in various
types of cancers have been observed in both the non-coding and
coding regions of mtDNA, but the majority of the mutations
identified have been described in the D-loop region (non-coding
region). Deletions, insertions in the D-loop region and transitions
have been observed in breast, hepatocellular and colorectal cancer
mtDNA deletions such as mtDNA4977 have been identified in
prostate cancer [12–14] and even some mtDNA mutations are
related with increased serum PSA[15,16].
The specific difficulties in understanding the causes of prostate
cancer are due to the heterogeneous nature of the disease, its
unknown etiology, and the fact that many of the genes involved
have multiple variations among populations, are greatly affected
by environmental factors among populations, and a large role for
environmental effects [17–19].
The aim of the present study was to compare the frequencies of
mtDNA haplogroups and CR (control region) polymorphisms in
239 patients with sporadic prostate cancer to those in 150 healthy
controls in Southwest Europe, as previously done in Korea [20]
and Middle European Caucasians [21].
Results
The nine major European mtDNA haplogroups and CR
polymorphisms were analyzed in whole blood samples of 239
patients with sporadic prostate cancer and were compared to 150
control subjects without any familial clinical history of the
pathology. Furthermore, controls were confirmed by normal
PSA values with blood levels below 4 ng/ml, as well as normal
rectal touch. The clinical characteristics of the patients and
controls are shown in Table 1.
mtDNA Haplogroup Distribution in Patients with
Sporadic Prostate Cancer
The frequencies of mitochondrial haplogroups did not differ
significantly between the patients with prostate cancer and the
control subjects (Table 2).
These nine main haplogroups were also compared with the
Spanish mitochondrial haplogroup distribution, as can be seen in
Figure 1.
CR Polymorphisms in Patients with Sporadic Prostate
Cancer
The mitochondrial CR were sequenced and analyzed between
nucleotide positions 16024 and 16365 (Tables S1 and S2). One
hundred twenty-four homoplasmic polymorphisms and a hetero-
plasmic polymorphism (16169Y) were found among the 389
subjects compared to the revised Cambridge reference sequence
[22]. Of the 125 polymorphisms detected, 13 were not listed in the
Human Mitochondrial Genome Database [23], and 1 was neither
listed in MITOMAP [24] nor the Human Mitochondrial Genome
Database [23].
Eighteen of the 125 CR polymorphisms were detected at a
frequency $4% in either the sporadic prostate cancer or the
control group (Table 3). These were subjected to further statistical
analysis. One of them, 16356C (p = 0.029) was found to have a
significantly higher frequency in patients with sporadic prostate
cancer compared to controls. Another polymorphism, 16278T has
a p-value of 0.051 (Table 3). However, the significance was lost
after correction for multiple comparisons by Bonferroni analysis, a
significance level of ,0.0004 is required.
Table 1. Characteristics of the study population.
Patients with
prostate cancer Controls
n = 239 n = 150
Mean (SD1) age (years) 66.9 (7.74) 70.2 (8.39)
Stage
A n = 9 (3.76%) n.a.
B n = 145 (60.67%) n.a.
C n = 49 (20.50%) n.a.
D n = 24 (10.04%) n.a.
Missing n = 12 (5.02%) n.a.
Gleason score
2–6 n = 150 (62.76%) n.a.
7 n = 45 (18.82%) n.a.
8–10 n = 29 (12.13%) n.a.
Missing n = 15 (6.27%) n.a.
PSA levels (ng/ml)
#4.0 n = 1 (0.42%) n.a.
4.1–10 n = 101 (42.26%) n.a.
10.1–20 n = 65 (27.19%) n.a.
.20 n = 42 (17.57%) n.a.
.1,000 n = 2 (0.84%) n.a.
Missing n = 28 (11.72%) n.a.
1SD, standard deviation; n.a., not applicable.
doi:10.1371/journal.pone.0041201.t001
Table 2. Frequencies (%) of European mitochondrial






n = 150 p-value1
H 45.6 (n = 109) 42.7 (n = 64) 0.570
I 0.8 (n = 2) 1.3 (n = 2) 0.637
J 7.9 (n = 19) 10.7 (n = 16) 0.362
K 6.3 (n = 15) 7.3 (n = 11) 0.684
T 5.9 (n = 14) 4.7 (n = 7) 0.613
U 16.3 (n = 39) 14.7 (n = 22) 0.663
W 1.7 (n = 4) 1.3 (n = 3) 0.791
X 1.3 (n = 3) 2 (n = 2) 0.562
V 0 (n = 0) 1.3 (n = 2) 0.073
Others2 14.2 (n = 34) 14 (n = 21) 0.950
1p-value: Pearson Chi-square.
2Haplogroups that could not be assigned to one of the nine major European
haplogroups (D, F, L, M, N, O, P and R).
doi:10.1371/journal.pone.0041201.t002
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The linkage disequilibrium analysis results show that some CR
polymorphisms were out of balance (p = 0.05); the standardized
disequilibrium values are shown in Table S3. The T16356C
substitution associated with patients (p = 0.029) is linked to
A16183C and T16189C (p,0.05). The mutation C16278T
(p = 0.051) is associated with C16069T, T16126C, T16172C,
T16189C, and C16223T (p,0.05).
Analysis of Clinical Parameters
We also analyzed the relation between the clinical parameters
associated with tumor invasiveness and progression (PSA levels,
Gleason score, and T-stage) and the haplogroup frequencies, as far
as CR polymorphism.
When the five most prevalent haplogroup frequencies were
compared with the main clinical parameters used to diagnose
prostate cancer (PSA levels, Gleason score, and T-stage), no
significance differences were observed among prostate cancer
patients (data not shown). Furthermore, when the clinical
parameters were subdivided into categories: PSA levels (#4.0,
4.1–10, 10.1–20, .20, .1,000), Gleason score (2–6, 7, 8–10), and
T-stage (A, B, C, D), none of the haplogroups reached statistical
significance (Table 4).
When analyzing the CR polymorphisms and clinical parameters
among patients, only significant differences were observed in
Gleason score and T-stage. The variant G16129A was found in
8.79% of the patients with a Gleason score between 2–6, in 0.42%
of the patients with a Gleason score of 7, and in 0.42% of the
patients with a Gleason score of 8–10 (p = 0.007). Also, the
mutation T16224C was found in 3.76% of the patients with a
Gleason score between 2–6, in 2.09% of the patients with a
Gleason score of 7, and in 0.41% of the patients with a Gleason
score of 8–10 (p = 0.022). The T16311C substitution reached
significance when compared to the four T-stage categories: 1.67%
of patients in category A, 9.21% in B, 1.67% in C, and 1.67% in D
(p = 0.046).
Discussion
Human mitochondrial DNA is widely used as a tool in many
fields, including evolutionary anthropology and population histo-
ry, medical genetics, genetic genealogy, and forensic science [25].
The main role of mitochondria related to malignancy and cancer
biology is likely due to their essential function in the generation of
ATP and the regulation of apoptosis [8]. Because of the high
mutation rate in the 1.1 kb non-coding control region (16024-
576), which is about ten times higher than the mutation rate in the
15.5 kb coding region (bases 577–16023) [26], the non-coding
region is relatively enriched in sequence variation, and haplogroup
information can be obtained from this region. These haplogroups
have been related to some oncological diseases, such as breast,
colorectal, and thyroid [27] cancer, as well as other diseases, such
as AIDS [28].
The most prevalent haplogroup in this population is H (45.6%
in patients and 42.7% in controls), which is also the most
widespread in Occidental Europe. We have also distinguished the
other eight main haplogroups found in the European population
(I, U, K, J, T, W, X, and V) [29] and, in a minority percentage,
the haplogroups D, F, L, M, N, O, P, and R. As can be seen from
the data, the haplogroups H, U, and W were more prevalent in
patients than in controls, whereas the haplogroups I, J, and K were
observed in controls (Table 2). Nevertheless, no significant
differences in haplogroup frequencies between patients with
Figure 1. Bar graph representing the mitochondrial haplogroups in patients, controls, and the Spanish population.
doi:10.1371/journal.pone.0041201.g001
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sporadic prostate cancer and control subjects could be found, as
also reported by Mueller et al. [21], who performed a case-control
study of 304 patients with prostate carcinoma in Middle Europe.
However, a study in a North American population of European
descendent reported an elevated presence of the haplogroup U in
prostate carcinoma patients [10]. One of the limitations of our
study is the restricted sample size (239 patients and 150 controls).
Comparing the haplogroups in this study with that in the
Spanish population [30], the percentages of mitochondrial
haplogroups in Spain were found to be very similar to the data
obtained in our analysis (46.53% H, 19.10% U, 9.03% T, 7.29%
J, 5.56% K, and 1.74% I) (Figure 1).
With regard to the clinical characteristic analysis, no association
was observed between mitochondrial haplogroup and age, PSA
serum levels, Gleason score, or T-stage. However, when all clinical
characteristics were categorized, no association was found with
any haplogroups due to the fact that the limited number of
patients enrolled was not enough for statistical analysis in small
subgroups. However, the highest PSA levels (10.1–20, .20, and
.1,000) and Gleason scores (7 and 8–10), and increased
proportions of T-stage C were found in patients with the
haplogroups H and U (Table 4).
The SNPs in the D-loop region have been examined in other
tumor types (pancreatic, breast, or melanoma, among others) [31–
33] as predictor factors of cancer risk. For this reason, we also
compared the CR germinal polymorphisms of mtDNA in sporadic
prostate cancer patients.
The T16356C variant has been previously related to glioblas-
toma [34] and breast cancer. In breast cancer, it has been included
like a germ-line sequence variation [35]. Within our prostate
cancer cohort, the T16356C mutation showed significantly
elevated frequencies in prostate cancer patients compared to
controls (p = 0.029). The C16278T polymorphism has also been
previously related to cancer, particularly to breast cancer in Tan
et al. [35], and to neurofibromatosis type-1 [36], as well as to other
disorders, such as Parkinson’s disease [37]. Among our prostate
cancer subjects, we have also found nearly significant elevated
frequencies in prostate cancer patients compared to controls
(p = 0.051). However, it is unclear whether these polymorphisms
may be involved in tumor formation or progression, or the
development of the other previously mentioned diseases.
The A16183C polymorphism has been established by MITO-
MAP [24] or the Human Mitochondrial Genome Database [23]
to be related to prostate cancer disease [11,38]. However, in our
cohort, we did not find a significant association between this
polymorphism and the disease (p = 0.428). In the analysis
performed by Jeronimo et al., the position 16183 has been
described as a mtDNA mutation in prostate cancer by the change
A R G [38]; studies performed by Makiko et al. has associated
this polymorphism to lung cancer patients [39].
We further analyzed the clinical parameters to determine if the
CR polymorphisms in the patient cohort correlate with disease
aggressiveness. The G16129A and T16224C polymorphisms were
found to be associated with less aggressive Gleason scores (2–6)
[40], with the scores closest to 2 as the least aggressive and those
next to 10 as the most aggressive [41]. The G16129A substitution
has been described in thyroid cancer and, in combination with
T16362C, could have an effect on mtDNA replication and/or
transcription, as well on increasing the risk of thyroid cancer [27].
On the other hand, the T16224C mutation has been described in
patients with nonmelanoma skin cancer, but no association with
the disease has been established [42]. On analyzing our results, no
strong relation could be established because the Gleason score
percentages of this variant were all below 5%. The T16311C
variant was found at higher frequency in patients with T-stage B
(also known as stage II), which includes cancers that have not
spread outside the prostate (local cancer) [43,44]. This polymor-
phism was previously described by Chen et al. [45] as a mtDNA
mutation detected in the D-loop region in neoplastic lesions
dissected from 16 prostatectomy specimens, but no information
about clinical features were provided; it has also been found to be
significantly associated with human colorectal cancer [46].
As only CR and mitochondrial haplogroups were analyzed,
mitochondrial coding region polymorphisms cannot be excluded
as possible mutations associated with prostate cancer [8,47].
Somatic mutations in mitochondrial DNA (mtDNA) have been
identified in various tumors, including breast cancer [48],
squamous cell carcinoma [49], and prostate cancer [15,50]. In
Table 4. Summary of statistical data on haplogroups in patients and clinical data.
Haplogroup H Haplogroup U Haplogroup K Haplogroup J Haplogroup T
% p-value % p-value % p-value % p-value % p-value
Age #55 7.1 8.8 8.3 9.1 9.1
56–60 10 0.431 (F) 5.9 0.431 (F) 8.3 0.431 (F) 18.2 0.431 (F) 36.4 0.431 (F)
61–65 24.3 0.371 (MC) 11.8 0.371 (MC) 8.3 0.371 (MC) 18.2 0.371 (MC) 9.1 0.371 (MC)
.65 58.6 73.5 75 54.5 45.5
Stage A 4.3 2.9 8.3 0 0
B 60.9 0.851 (F) 58.8 0.851 (F) 75 0.851 (F) 81.8 0.851 (F) 54.5 0.851 (F)
C 24.6 0.837 (MC) 29.4 0.837 (MC) 8.3 0.837 (MC) 9.1 0.837 (MC) 18.2 0.837 (MC)
D 10.1 8.8 8.3 9.1 27.3
PSA #4.0 0.8 0 0 0 0
4.1–10 47.6 48.4 36.4 45.5 36.4
10.1–20 27 0.723 (F) 29 0.723 (F) 27.3 0.723 (F) 54.5 0.723 (F) 27.3 0.723 (F)
.20 20.6 0.679 (MC) 19.4 0.679 (MC) 18.2 0.679 (MC) 0 0.679 (MC) 18.2 0.679 (MC)
.1000 4 3.2 18.2 0 18.2
Vr, versomility reason; cv, contingency value; F, Fisher; MC, Monte Carlo; %, % of haplogroup in patients.
doi:10.1371/journal.pone.0041201.t004
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squamous cell carcinoma, they were associated with better
survival. However, in breast cancer somatic mutations are
suggested to play a critical role in the progression of the cancer.
Somatic mutations are frequent events in prostate cancer.
Mutations mapping to mitochondrial tRNAs, ribosomal RNAs,
and protein coding genes might impair processes that occur within
the mitochondrial compartment (e.g., transcription, RNA pro-
cessing, and translation) and might ultimately affect oxidative
phosphorylation [15]. Germline and somatic mutations have also
been described in patients with uterine fibroids [51] and prostate
cancer [50], but there is not as much information on these as for
somatic mutations in cancer. In this study, only blood genomic
DNA samples were available, and no associations between somatic
mutations could be determined.
In conclusion, our study confirms the lack of association




This study complied with the Declaration of Helsinki. Informed
consent was obtained from all subjects before they were entered
into the study. The study and use of archive samples for this
project were approved by the Ethics Committee of the University
‘‘Hospital Virgen de las Nieves,’’ Granada, Spain.
Patients and Controls
Patients with sporadic prostate cancer were selected by a
urologist, who also made notations about important parameters
for prostate cancer, such as PSA level, T-score, Gleason score, and
other information, including age, place of birth, and family history
of prostate cancer. In brief, the eligible patients were adult males
with a recent diagnosis of prostate cancer (n = 239). The clinical
features of the patients selected for the study were histopatholog-
ically confirmed primary adenocarcinoma after abnormal serum
PSA findings and/or lower urinary tract symptoms. Our patients
were unrelated European men with a mean age of 67.4 years and a
mean Gleason score of 7.0, which indicates a dominant growth
pattern of the tumor [52–54]. Healthy unrelated European men
(n = 150) from the same geographic area with no history of prostate
cancer were enrolled as controls (no PSA levels were detected and
clinical evolution over some years was followed to avoid including
affected men with prostate cancer as controls). Controls belonged to
the same age group as patients; they all were men with health
problems like renal lithiasis or andrological problems, so PSA
analysis was performed to dismiss a possible prostate cancer. They
all have normal PSA values with blood levels below 4 ng/ml, as well
as a normal rectal touch. Informed consent was obtained from all
the subjects in this study, which was approved by the Ethics
Committee of the hospital. Peripheral blood samples were drawn
from all participants (n = 389) into tubes containing K3-EDTA.
DNA Extraction and Genotyping
Genomic DNA from patients and controls was extracted from
peripheral blood using the standard organic extraction procedure
by phenol/chloroform/isoamyl alcohol and proteinase K, and
purification with MicroconH 100 filters (Millipore). Mitochondrial
DNA sequencing and haplotyping were performed using Ampli-
Taq GoldH PCR Master Mix (Applied Biosystems), which includes
all of the chemical components, except the primers and template,
necessary for PCR in a GeneAmp System 2400 thermal cycler.
Each PCR reaction was performed in a total volume of 25 mL
containing 1–2 ng/mL of DNA, 0.5 mL of each primer covering
the HVI (nucleotide positions 16024–16365) region, and 12.5 mL
of AmpliTaq GoldH PCR Master Mix (Applied Biosystems). The
amplification conditions were 95 uC for 11 min followed by
32 cycles at 95 uC for 10 sec, at 60 uC for 30 sec, and at 72 uC for
30 sec. The amplicons were purified using MicroconH 100 filters
(Millipore). Sequencing reactions were performed using ABI
PRISMH BigDye Terminator v.1.1 Cycle Sequencing Ready
Reaction Kits. Each sequencing reaction was performed in a total
volume of 10 mL containing 3 mL of DNA, 3 mL of each specific
primer, 2 mL of kit, and 2 mL of buffer from the ABI PRISMH
BigDye Terminator v.3.1 kit. The thermal cycling conditions were
95 uC for 1 min followed by 25 cycles at 95 uC for 15 sec, at 50 uC
for 1 sec, and at 60 uC for 2 min. The excess dye terminator was
removed by gel filtration with Performa H DTR Cartridges
(EdgeBio) and analyzed using the automated DNA sequencer ABI
PRISMH 3130 (Applied Biosystems). The results of the analysis
were edited using the ABI PRISMH SeqScapeH v.2.6 software.
Haplotype Tagging and Statistical Analysis
Haplogroups are defined by CR polymorphisms and any giving
range of the mitochondrial genome can be used for haplogroup
classification, which is based on the phylogenetic stability of
mtDNA polymorphisms. The assignment of haplogroups to the
samples was done using online software for mitochondrial DNA,
such as the Haplogroup Prediction Tool of ‘‘The Genographic
Project’’ [55], Aplo haplogroup search [56], and mtDNA manager
[57]. Furthermore, all the haplogroups in this study were
confirmed by Web programs, such as HaploGrep [58] and
Phylotree [25]. Obtained results were analyzed and revised by
expertise personal in the area by the presence or lack of some
positions in comparison with reference sequence and checked by
the use of last version available at Phylotree [25].
Using the software package SPSS v.15.0 [59], we performed
statistical analyses, including the x2 test, Fisher’s exact test, Monte
Carlo testing, and generated contingency tables. The frequencies
of all mitochondrial haplogroups and CR polymorphisms in the
prostate cancer patients and controls were tested for independency
using Pearson chi-square statistics and Fishers exact test as
appropriate. These analyses were performed to test for indepen-
dence between the haplogroup data and the clinical data, such as
age (#55, 56–60, 61–65, .65), Gleason score (2–6, 7, 8–10), T-
stage (A, B, C, D), and PSA levels (#4.0, 4.1–10, 10.1–20, .20,
.1,000). All tests considered the nominal statistical significance (p-
value) to be ,0.05. Only CR variants with a frequency $4% in
either the prostate cancer or the control group were subjected to
further statistical analysis. Association of T16356C with the disease
was adjusted for age by logistic regression analysis. For analysis of
T16356C polymorphism significant p-value was corrected for
multiple comparisons by Bonferroni analysis leading to a new
required significance level of ,0.0004 (number of compari-
sons = 125). Linkage disequilibrium analysis was performed
between all pairs of CR polymorphisms using 10,000 steps in
the Markov Chain and 1,000 dememorization steps. D, D9, and r2
coefficients were computed with a significance level of 0.05 using
the Arlequin v3.5 software [60].
Supporting Information
Table S1 Control region polymorphisms and haplogroup
classification for 239 patients with sporadic prostate cancer.
(PDF)
Table S2 Control region polymorphisms and haplogroup
classification for 150 controls with sporadic prostate cancer.
(PDF)
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the data: MJÁC MSG LJMG. Contributed reagents/materials/analysis
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